法布瑞氏症治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按藥物、按治療、按給藥途徑、按配銷通路、按地區和競爭進行細分，2020-2030 年預測

2024 年全球法布瑞氏症治療市場價值為 18.6 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 6.30%。法布瑞氏症，也稱為安德森-法布瑞氏症，是一種罕見的遺傳性疾病，屬於一類被稱為溶小體貯積症的疾病。這種疾病是由 GLA 基因突變引起的，該基因編碼一種稱為 α-半乳糖苷酶 A（alpha-Gal A）的酶。這種酵素的缺乏會導致全身細胞內積聚一種特定類型的脂肪物質，稱為神經醯胺三己糖基（Gb3 或 GL-3）。 Gb3 的積聚主要影響血管、腎臟、心臟和神經系統的細胞，導致多種症狀和併發症。法布瑞氏症的症狀通常出現在兒童期或青少年期，但症狀出現的年齡及其嚴重程度在受影響的個體之間可能存在很大差異。法布瑞氏症的典型症狀之一是神經性疼痛，這種疼痛可能很嚴重且是慢性的。這種疼痛通常影響手和腳等四肢，通常被描述為灼熱或刺痛。例如，根據國家法布瑞氏症基金會（NFDF）的數據，美國每年將四月定為法布瑞氏症宣傳月。宣傳計劃專注於教育公眾、患者、護理人員和醫療保健專業人員。這些措施旨在提高對法布瑞氏症的理解、診斷和管理，最終促進整個研究期間的市場成長。

主要市場促進因素

診斷方面的進展

主要市場挑戰

患者數量有限

主要市場趨勢

生物標記開發

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：全球法布瑞氏症治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 透過藥物（Agalsidase Beta、Migalastat 等）
  • 依治療（酵素替代療法 (ERT)、伴侶治療、底物減少療法 (SRT)、其他）
  • 依給藥途徑（口服、腸胃外、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區法布瑞氏症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲法布瑞氏症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美法布瑞氏症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲法布瑞氏症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲法布瑞氏症治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球法布瑞氏症治療市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Sanofi (Genzyme Corporation)
• Takeda Pharmaceutical Company Limited
• Amicus Therapeutics, Inc
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Chiesi Farmaceutici SpA
• Freeline Therapeutics Holdings PLC
• Yuhan Corporation
• M6P Therapeutics
• ISU Abxis Co Ltd

第 17 章：策略建議

第18章調查會社について,免責事項

Global Fabry Disease Treatment Market was valued at USD 1.86 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.30% through 2030. Fabry disease, also known as Anderson-Fabry disease, is a rare and inherited genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. This disease is caused by mutations in the GLA gene, which encodes an enzyme called alpha-galactosidase A (alpha-Gal A). The deficiency of this enzyme results in the accumulation of a specific type of fatty substance, known as globotriaosylceramide (Gb3 or GL-3), within cells throughout the body. This buildup of Gb3 primarily affects the cells of blood vessels, kidneys, heart, and nervous system, leading to a wide range of symptoms and complications. Symptoms of Fabry disease often appear in childhood or adolescence, although the age of symptom onset and their severity can vary widely among affected individuals. One of the hallmark symptoms of Fabry disease is neuropathic pain, which can be severe and chronic. This pain typically affects the extremities, such as the hands and feet, and is often described as burning or tingling. For instance, according to the National Fabry Disease Foundation (NFDF) designates April as Fabry Disease Awareness Month each year in the United States. Awareness programs focus on educating the public, patients, caregivers, and healthcare professionals. These initiatives aim to improve the understanding, diagnosis, and management of Fabry disease, ultimately contributing to market growth throughout the study period.

Key Market Drivers

Advancements in Diagnosis

Genetic testing has become a cornerstone in the diagnosis of Fabry disease. Advances in genetic sequencing technology have made it more accessible and cost-effective to identify specific mutations in the GLA gene, which is responsible for the disease. Genetic testing can confirm the presence of Fabry disease and provide information about the specific genetic mutations involved. In some regions, newborn screening programs have been implemented to identify Fabry disease in infants shortly after birth. This early detection allows for prompt intervention and treatment, potentially preventing or delaying the onset of symptoms and organ damage. Researchers have been investigating biomarkers associated with Fabry disease. Biomarkers are measurable substances in the body that can indicate the presence of a disease or its progression. Biomarker research can aid in early diagnosis and monitoring the effectiveness of treatment. Clinical diagnostic criteria for Fabry disease have been refined and standardized. Healthcare professionals now have clearer guidelines and criteria to assist in diagnosing disease based on clinical symptoms and genetic testing results. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to assess the efficacy and safety of AGA BETA BS in FD patients previously stabilized with Fabrazyme. Also, Fabry disease pipeline products continue to drive market growth. For example, in August 2021, the European Commission approved Amicus Therapeutics' Galafold for long-term treatment of Fabry disease in patients aged 12 and above with an amenable mutation.

Key Market Challenges

Limited Patient Population

The small patient population with Fabry disease results in a limited market size for pharmaceutical companies. This can make it less economically attractive for these companies to invest in research and development of treatments for disease. Developing and gaining regulatory approval for new treatments, including clinical trials and research, is costly. In the case of rare diseases like Fabry disease, the small number of potential patients can make it challenging to recoup these expenses. Due to the small market size, the revenue potential for treatments for Fabry disease may be limited compared to drugs for more common conditions. This can affect the profitability of drug development efforts. Limited patient populations can result in challenges related to patient access to treatments and affordability. Even if effective treatments exist, they may not be accessible to all patients due to cost or availability. The rarity of Fabry disease can lead to delayed diagnosis or misdiagnosis, as healthcare providers may not be familiar with the condition. This can result in patients not receiving appropriate treatment until the disease has progressed. Limited patient populations can also result in a scarcity of clinical data on the disease and its treatment. This can make it challenging for healthcare providers to make informed treatment decisions. Recognizing the challenges posed by rare diseases, some regulatory agencies provide incentives for orphan drug development. These incentives can include extended market exclusivity and reduced regulatory fees.

Key Market Trends

Biomarker Development

Biomarkers can aid in the early diagnosis of Fabry disease, allowing for timely intervention and treatment initiation. Early diagnosis is essential for preventing or delaying the onset of symptoms and organ damage. Biomarkers can be used to monitor disease progression and assess the effectiveness of treatment over time. This enables healthcare providers to tailor treatment plans to individual patients' needs. Certain biomarkers may be associated with the severity of Fabry disease. Identifying these biomarkers can help predict disease outcomes and guide treatment decisions. Biomarkers can help determine how well a patient is responding to treatment. If treatment is effective, biomarkers may show improvements in disease-related indicators. Biomarkers can serve as valuable endpoints in clinical trials of new Fabry disease treatments. They provide objective measures of treatment efficacy and safety. The development of biomarkers supports the concept of personalized medicine, where treatments are tailored to individual patients based on their biomarker profiles. This approach can optimize treatment outcomes. Biomarkers provide insights into the underlying molecular and genetic mechanisms of Fabry disease. This knowledge can inform drug development efforts, leading to more targeted and effective therapies. Biomarkers can be used to stratify Fabry disease patients into different subgroups based on disease characteristics. This stratification can guide treatment decisions and improve patient outcomes. Biomarkers can help reduce diagnostic delays by providing objective evidence of Fabry disease. This is particularly important because Fabry disease is often underdiagnosed or misdiagnosed.

Key Market Players

• Sanofi (Genzyme Corporation)
• Takeda Pharmaceutical Company Limited
• Amicus Therapeutics, Inc
• ISU ABXIS Co Ltd.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Chiesi Farmaceutici S.p.A.
• Freeline Therapeutics Holdings PLC
• Yuhan Corporation
• M6P Therapeutics Inc.

Report Scope:

In this report, the Global Fabry Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fabry Disease Treatment Market, By Drugs:

• Agalsidase Beta
• Migalastat
• others

Fabry Disease Treatment Market, By Treatment:

• Enzyme Replacement Therapy (ERT)
• Chaperone Treatment
• Substrate Reduction Therapy (SRT)
• Others

Fabry Disease Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Others

Fabry Disease Treatment Market, By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies
• Online Pharmacies

Fabry Disease Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fabry Disease Treatment Market.

Available Customizations:

Global Fabry Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fabry Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Agalsidase Beta, Migalastat, others)
  • 5.2.2. By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, others)
  • 5.2.4. By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Fabry Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Fabry Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Fabry Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Fabry Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Fabry Disease Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drugs
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Fabry Disease Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drugs
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. Europe Fabry Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Fabry Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Fabry Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Fabry Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Fabry Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Fabry Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. North America Fabry Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Fabry Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Fabry Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Fabry Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. South America Fabry Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Fabry Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Fabry Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Fabry Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Fabry Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Fabry Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Fabry Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Fabry Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Fabry Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Sanofi (Genzyme Corporation)
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Takeda Pharmaceutical Company Limited
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Amicus Therapeutics, Inc
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. JCR Pharmaceuticals Co., Ltd.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Protalix BioTherapeutics Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Chiesi Farmaceutici S.p.A.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Freeline Therapeutics Holdings PLC
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Yuhan Corporation
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. M6P Therapeutics
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.ISU Abxis Co Ltd
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer